Q1 2025 Earnings Forecast for ChromaDex Co. (NASDAQ:CDXC) Issued By Roth Capital

ChromaDex Co. (NASDAQ:CDXC) – Equities research analysts at Roth Capital cut their Q1 2025 earnings per share estimates for shares of ChromaDex in a report released on Thursday, May 9th. Roth Capital analyst S. Mcgowan now anticipates that the company will post earnings per share of $0.00 for the quarter, down from their prior estimate of $0.01. The consensus estimate for ChromaDex’s current full-year earnings is ($0.02) per share. Roth Capital also issued estimates for ChromaDex’s Q3 2025 earnings at $0.01 EPS.

Several other equities research analysts have also issued reports on the stock. Roth Mkm increased their target price on shares of ChromaDex from $4.25 to $6.00 and gave the stock a “buy” rating in a report on Tuesday, April 9th. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of ChromaDex in a research note on Thursday. Finally, StockNews.com assumed coverage on shares of ChromaDex in a research note on Sunday, March 3rd. They set a “strong-buy” rating on the stock.

ChromaDex Stock Up 0.3 %

NASDAQ CDXC opened at $3.53 on Friday. ChromaDex has a 52 week low of $1.25 and a 52 week high of $4.65. The company has a market capitalization of $266.60 million, a P/E ratio of -50.29 and a beta of 1.96. The stock’s 50-day moving average price is $3.25 and its 200-day moving average price is $2.08.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gamco Investors INC. ET AL boosted its position in shares of ChromaDex by 26.5% during the third quarter. Gamco Investors INC. ET AL now owns 259,850 shares of the company’s stock worth $379,000 after acquiring an additional 54,500 shares during the last quarter. Gabelli Funds LLC lifted its stake in ChromaDex by 9.1% in the 3rd quarter. Gabelli Funds LLC now owns 180,000 shares of the company’s stock worth $263,000 after purchasing an additional 15,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of ChromaDex by 121.9% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,031 shares of the company’s stock valued at $121,000 after purchasing an additional 45,618 shares during the last quarter. Silverberg Bernstein Capital Management LLC purchased a new position in shares of ChromaDex during the fourth quarter valued at about $118,000. Finally, International Assets Investment Management LLC increased its holdings in shares of ChromaDex by 43.0% in the fourth quarter. International Assets Investment Management LLC now owns 28,600 shares of the company’s stock worth $410,000 after purchasing an additional 8,600 shares during the last quarter. 15.41% of the stock is currently owned by institutional investors.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.